Literature DB >> 17005750

Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load.

L Perrin1, J M Pawlotsky, M Bouvier-Alias, C Sarrazin, S Zeuzem, G Colucci.   

Abstract

A TaqMan real-time PCR assay, the COBAS TaqMan human immunodeficiency virus (HIV) (HPS-CTMHIV) PCR assay, recently developed for the quantification of HIV type 1 RNA in plasma, was evaluated in comparison with the licensed COBAS AMPLICOR HIV-1 MONITOR (CAHIM) assay. In this study, we have analyzed the tests' sensitivities, precisions, and linearities using multiple replicates of a standard panel of HIV RNA covering a 7-logarithm range of concentrations, as well as serial threefold dilutions of high-titer clinical samples. The subtype inclusivity was also investigated, using a panel of subtypes A to H, while a collection of 160 clinical samples was analyzed to assess the tests' specificities and the systems' similarities. The results of these experiments showed that the HPS-CTMHIV assay has a sensitivity of 53 copies/ml (95% hit rate), 100% specificity, and good intra- and interassay precision. The results of the HPS-CTMHIV assay were linear in the 50- to 10(7)-copies/ml range, with a correlation coefficient (R) for expected versus observed results of 0.98. Compared to the CAHIM assay, the HPS-CTMHIV assay showed a high correlation (R=0.99) across the dynamic range of RNA concentrations that, for the CAHIM assay, requires two different sample preparations. Equivalent performances were also observed for the two systems in the detection and quantification of HIV subtypes A to H. These data indicate that the HPS-CTMHIV assay may be one of the tests of choice for monitoring viral load throughout the course of HIV infection and during highly active antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005750      PMCID: PMC1698437          DOI: 10.1128/JCM.00505-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa.

Authors:  W Stevens; T Wiggill; P Horsfield; L Coetzee; L E Scott
Journal:  J Virol Methods       Date:  2004-12-15       Impact factor: 2.014

2.  An internal control for routine diagnostic PCR: design, properties, and effect on clinical performance.

Authors:  M Rosenstraus; Z Wang; S Y Chang; D DeBonville; J P Spadoro
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

3.  A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.

Authors:  M L Collins; B Irvine; D Tyner; E Fine; C Zayati; C Chang; T Horn; D Ahle; J Detmer; L P Shen; J Kolberg; S Bushnell; M S Urdea; D D Ho
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

4.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

5.  Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; E S Daar; M S Simberkoff; J D Hamilton
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

6.  Genotyping of B and non-B subtypes of human immunodeficiency virus type 1.

Authors:  C Y W Tong; J Mullen; R Kulasegaram; A De Ruiter; S O'Shea; I L Chrystie
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  R Sun; J Ku; H Jayakar; J C Kuo; D Brambilla; S Herman; M Rosenstraus; J Spadoro
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

8.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Authors:  D A Katzenstein; S M Hammer; M D Hughes; H Gundacker; J B Jackson; S Fiscus; S Rasheed; T Elbeik; R Reichman; A Japour; T C Merigan; M S Hirsch
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

9.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  10 in total

1.  Performance of NucliSens HIV-1 EasyQ Version 2.0 compared with six commercially available quantitative nucleic acid assays for detection of HIV-1 in China.

Authors:  Sihong Xu; Aijing Song; Jianhui Nie; Xiuhua Li; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-10-01       Impact factor: 4.074

2.  Modeling uncertainty in single-copy assays for HIV.

Authors:  Rutao Luo; Michael J Piovoso; Ryan Zurakowski
Journal:  J Clin Microbiol       Date:  2012-07-25       Impact factor: 5.948

3.  Robust closed-loop minimal sampling method for HIV therapy switching strategies.

Authors:  E F Cardozo; R Zurakowski
Journal:  IEEE Trans Biomed Eng       Date:  2012-05-25       Impact factor: 4.538

4.  Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching.

Authors:  E Fabian Cardozo; Ryan Zurakowski
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2011

5.  Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.

Authors:  Cheryl Jennings; Brian Harty; Suzanne Granger; Carrie Wager; John A Crump; Susan A Fiscus; James W Bremer
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

6.  Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay.

Authors:  Anthony R Oliver; Spyridon F Pereira; Duncan A Clark
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

7.  Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays.

Authors:  Lesley E Scott; Lara D Noble; Jackie Moloi; Linda Erasmus; Willem D F Venter; Wendy Stevens
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

8.  Monitoring HIV vaccine trial participants for primary infection: studies in the SIV/macaque model.

Authors:  James B Whitney; Corinne Luedemann; Saran Bao; Ayako Miura; Srinivas S Rao; John R Mascola; Norman L Letvin
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

9.  Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay.

Authors:  A De Bel; D Marissens; L Debaisieux; C Liesnard; S Van den Wijngaert; S Lauwers; D Piérard
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

10.  Modelling HIV-1 2-LTR dynamics following raltegravir intensification.

Authors:  Rutao Luo; E Fabian Cardozo; Michael J Piovoso; Hulin Wu; Maria J Buzon; Javier Martinez-Picado; Ryan Zurakowski
Journal:  J R Soc Interface       Date:  2013-05-08       Impact factor: 4.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.